ReviewCardiovascular research2022
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
Review in Cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk.International journal of molecular sciences · 2022Pooled it
- Correlation between serum and plasma lipoprotein(a) measurements: ARIC study.Journal of clinical lipidology · 2026Article
- The Relationship between Inflammation-Oxidative Stress and Lipoprotein (a) Levels in Healthy Subjects.Acta Cardiologica Sinica · 2026Article
- Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study.JACC. Advances · 2026Article
- The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice.Reviews in cardiovascular medicine · 2026Review
- Metabolic implications of COVID-19 with a focus on lipid profiles and inflammatory markers.Scientific reports · 2026Article
- Systemic inflammation modulates lipoprotein(a)-associated coronary stenosis in the chronic coronary syndromes.American journal of preventive cardiology · 2025Article
- Automated Deep Learning-Based Detection of Early Atherosclerotic Plaques in Carotid Ultrasound Imaging.medRxiv : the preprint server for health sciences · 2025Article
- Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature.World journal of cardiology · 2025Review
- Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome.Pharmaceutics · 2025Review
- Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases.Scientific reports · 2025Article
- Recent Advances in Immune Regulation by Targeting Dendritic Cells using Small Interfering RNAs.Current molecular medicine · 2025Review
- Deciphering Oxidative Stress in Cardiovascular Disease Progression: A Blueprint for Mechanistic Understanding and Therapeutic Innovation.Antioxidants (Basel, Switzerland) · 2024Review
- Article
- Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk.Journal of clinical medicine · 2024Article
- Atherosclerosis originating from childhood: Specific features.Journal of biomedical research · 2024Article
- Apolipoprotein(a) production and clearance are associated with plasma IL-6 and IL-18 levels, dependent on ethnicity.Atherosclerosis · 2024Article
- Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations.American heart journal plus : cardiology research and practice · 2024Article
- Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk.Current vascular pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein(a) [Lp(a)]-targeting therapy has yet been shown to reduce cardiovascular disease risk. Many epidemiological and genetic studies have demonstrated that Lp(a) is an important genetically determined causal risk factor for coronary heart disease, aortic valve disease, stroke, heart failure, and peripheral vascular disease. Accordingly, the need for specific Lp(a)-lowering therapy has become a major public health priority. Approximately 20% of the global population (1.4 billion people) have elevated levels of Lp(a) associated with higher cardiovascular risk, though the threshold for determining 'high risk' is debated. Traditional lifestyle approaches to cardiovascular risk reduction are ineffective at lowering Lp(a). To address a lifelong risk factor unmodifiable by non-pharmacological means, Lp(a)-lowering therapy needs to be safe, highly effective, and tolerable for a patient population who will likely require several decades of treatment. N-acetylgalactosamine-conjugated gene silencing therapeutics, such as small interfering RNA (siRNA) and antisense oligonucleotide targeting LPA, are ideally suited for this application, offering a highly tissue- and target transcript-specific approach with the potential for safe and durable Lp(a) lowering with as few as three or four doses per year. In this review, we evaluate the causal role of Lp(a) across the cardiovascular disease spectrum, examine the role of established lipid-modifying therapies in lowering Lp(a), and focus on the anticipated role for siRNA therapeutics in treating and preventing Lp(a)-related disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.